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cryoglobulinemic GN according to the clinical presentation. 
Immunosuppressive therapy is recommended for HCV-relat-
ed kidney disease having aggressive course, and recent evi-
dence supports rituximab (RTX) use with a reduced expo-
sure to corticosteroids. We identified six studies (66 unique 
patients) on RTX therapy for HCV-associated kidney disease; 
at the end of RTX therapy, the pooled estimate of the mean 
decrease in proteinuria was 1.4 g/24 h (95% CI: 0.75, 2.05, p  ! 
0.001); The p test for heterogeneity gave a value of 0.94
(I 2 = 0). Several questions related to RTX use remain. HCV-
induced GN is uncommon among CKD patients of devel-
oped countries, and this clearly hampers prospective con-
trolled clinical trials aimed to evaluate efficacy and safety of 
antiviral or immunosuppressive therapy in this population. 
 Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Patients with long-standing HCV infection can devel-
op chronic hepatitis, liver cirrhosis, and hepatocellular 
carcinoma. Several extrahepatic complications have also 
been associated with HCV including hematologic and 
dermatologic diseases as well as autoimmune and kidney 
diseases  [1] . A strong relationship between HCV infec-
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 Abstract 
 We describe the case of a 51-year-old woman with HCV- 
associated cryoglobulinemic glomerulonephritis (GN). She 
presented mild deterioration of kidney function, non-ne-
phrotic proteinuria, and active urinary sediment. Kidney bi-
opsy showed features of membranoproliferative changes 
with some sclerosis. Sustained viral response (SVR) was ob-
tained by 6 months of antiviral therapy (peg-IFN-  2a plus 
ribavirin). SVR was linked with improvement of kidney func-
tion and remission of proteinuria. Clinical and virological re-
mission persists over a 25-month follow-up. This case report 
emphasizes efficacy and safety of antiviral treatment of HCV-
associated glomerulonephritis – preliminary but encourag-
ing results exist. We identified by systematic review of the 
literature 9 studies (156 unique patients); the pooled esti-
mate of frequency of sustained virological response after 
IFN-based therapy was 0.49 (95% confidence interval, CI: 
0.21, 0.77; p  ! 0.0005; random effects model). Heterogeneity 
was found (I 2 = 98.9%, p  ! 0.0001). Two possible regimens 
should be considered for the treatment of HCV-associated 
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tion and cryoglobulinemia has been found since early 
1990s  [2, 3] . More recent evidence has been accumulated 
showing a link between HCV infection and immune 
complex glomerular diseases, including membranopro-
liferative glomerulonephritis (MPGN) and membranous 
nephropathy  [4–7] . Less frequently described lesions are 
MPGN without cryoglobulinemia, focal segmental glo-
merulosclerosis, IgA nephropathy or fibrillary and im-
munotactoid glomerulopathies  [4–7] . Hepatitis C virus-
associated tubulointerstitial injury has also been report-
ed  [8] .
 The discovery of HCV and a better understanding of 
pathophysiological mechanisms provided the opportu-
nity to control HCV-associated MPGN using various ap-
proaches: (1) antiviral therapy based on the belief that the 
underlying infection is driving immune complex forma-
tion and resultant vasculitis; (2) non-specific immuno-
suppressive therapy targeting inflammatory cells present 
in vasculitic lesions, and (3) B cell depletion therapy tar-
geting B cells which produce cryoglobulins. It is clear that 
prospective randomized, controlled clinical trials (RCTs) 
are mandatory to make evidence-based recommenda-
tions to treat HCV-associated glomerulonephritis (GN) 
 [9] . Until this information is available, two possible regi-
mens have been recommended for the treatment of cryo-
globulinemic or non-cryoglobulinemic HCV-associated 
GN, depending on the severity of proteinuria and kidney 
failure ( table  1 ). In patients with moderate proteinuria 
and slow loss of kidney function, antiviral therapy tar-
geted at achieving clearance of HCV RNA with sustained 
viral response (SVR) has been successfully used. The use 
of steroid pulses with cytotoxic agents and plasma ex-
change has been suggested for patients with nephrotic 
proteinuria, and/or rapidly progressive loss of kidney 
function and an acute flare of cryoglobulinemia; after 
control of the vasculitic syndrome has been achieved, an-
tiviral therapy should be started  [9] .
 We report herein a case of HCV-related MPGN that 
was successfully treated with antiviral therapy. A system-
atic review of the literature on the efficacy and safety of 
therapy for HCV-associated GN was also performed.
 Case Report 
 A 51-year-old Caucasian female was diagnosed with chronic 
hepatitis C (genotype 2) in May 1998. She showed palpable pur-
pura that was first treated with methotrexate, chloroquine, and 
then low-dose oral corticosteroids. In June 1998, electromyogra-
phy revealed axonal neuropathy with sensitive abnormalities of 
the legs. In January 2009, she was admitted to the Division of Di-
gestive Diseases, Maggiore Hospital, for multifactorial anemia (at 
that time, serum creatinine 1.36 mg/dl). Several erosions at the 
duodenum with active bleeding were detected by endoscopy. Be-
ginning in September 2009, the patient had a progressive decline 
of the kidney function (serum creatinine rose from 1.36 to a max-
imum of 1.67 mg/dl) with non-nephrotic proteinuria (2 g/24 h). 
Arterial hypertension occurred, and therapy with angiotensin-
converting enzyme inhibitors and angiotensin receptor blockers 
was instituted with a small benefit on proteinuria. The patient was 
admitted (October 2009) to the Nephrology Division, Maggiore 
Hospital, and renal biopsy was performed. On physical examina-
tion, palpable purpura extended to the trunk with bilateral edema 
of the lower extremities. Serum creatinine was 1.3 mg/dl, anti-
HCV positive, HCV RNA positive (13,762 copies/ml), cryocrit was 
1%, rheumatoid factor 276 IU/l (0–14 IU/l), and C4 concentration 
10 mg/dl (17–33 mg/dl). She had a monoclonal IgMk cryoglobulin 
with a polyclonal IgG component. Normal serum immunoglobu-
lins (IgG, IgA, IgM), complement C 3 and electrophoresis were 
found. Several serologic markers were in the normal range includ-
ing anti-nuclear antibody, anti-double-stranded DNA (anti-
DNA), and anti-neutrophil cytoplasmic antibodies. Other find-
ings included GOT 16 IU/l, GPT 9 IU/l,   -glutamyltranspeptidase 
8 IU/l, and total bilirubin 0.15 mg/dl. Proteinuria was 1.13 g/24 h, 
and urine sediment, analyzed by phase-contrast microscopy, 
showed severe microscopic hematuria (90–100 erythrocytes/
microscopic field, 56% having dysmorphic nature, 12% acan-
thocytes), and numerous granular, and red cell casts. Kidney 
 histology showed 21 glomeruli, 16 of which were diffusely and 
uniformly abnormal with features characteristic of membrano-
proliferative nephritis (double contour appearance of the capil-
lary wall, centrolobular sclerosis, mesangial cell proliferation, en-
doluminal mononuclear cells, and mesangial matrix expansion). 
Table 1.  Treatment of HCV-related glomerular disease according 
to the clinical presentation
Patients with mild proteinuria and slow progressive kidney failure
– Anti-HCV therapy for 12 months
–
–
Pegylated IFN2a: 180 g/week SQ (135 g/week in patients 
with reduced glomerular filtration rate)
Pegylated IFN2b: 1.5 g/kg/week SQ (1.0 g/week in 
patients with low GFR)
– Ribavirin 800–1,200 mg day orally (for patients with GFR 
<50 ml/min: low ribavirin dose, 200–600 mg/day, and 
erythropoietin supplementation)
– Symptomatic therapy: ACE inhibitors and/or angiotensin 
receptor blockers to reduce proteinuria, diuretics
Patients with nephrotic proteinuria and/or progressive kidney 
failure
– Methylprednisolone pulses: 0.5–1.0 g/day for three 
consecutive days, then oral corticosteroids
– Cyclophosphamide: 1.5–2.0 mg/kg/day (2–4 months; oral route)
– RTX: 375 mg/m2/week for 4 weeks (intravenous route)
– Plasma exchange: 3 l of plasma thrice weekly for 2–3 weeks
– Anti-HCV therapy for 12 months (as shown above)
– Symptomatic therapy (as shown above)
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Global sclerosis was observed in five glomeruli. Interstitial fibro-
sis and moderate atherosclerosis were also present. Immunofluo-
rescence exhibited isolated IgM deposition in sclerotic areas. An-
tiviral therapy was started (subcutaneous administration of peg-
IFN-  2a 180   g weekly and oral ribavirin 400 mg twice a day), 
and prednisone therapy (5 mg on alternate days) was continued. 
Subcutaneous darbepoetin (40   g weekly) was also given.
 Complete resolution of the cutaneous manifestations and 
edema was noted after a few weeks of antiviral therapy. The pa-
tient required transfusion with 3 units of packed red blood cells 
(January 2010) due to severe anemia (Hb 6.8 g/dl); thus, therapy 
was modified as follows: peg-IFN-  135   g s.c. weekly, ribavirin 
200 mg twice a day, no prednisone, and darbepoetin dose pro-
gressively was increased to 100   g weekly. HCV RNA clearance 
occurred in January 2010. Antiviral therapy was discontinued 
in April 2010; at that time, the patient had normal protein excre-
tion (0.09 g/24 h) with very mild microscopic hematuria. A slow 
improvement of kidney function was found with serum creati-
nine 1.16 mg/dl. HCV RNA and serum cryoglobulin tests were 
repeatedly negative. Twenty-five months after completing anti-
viral therapy (May 2012), continued follow-up showed stable 
clinical conditions – proteinuria of 0.15 g/24 h, serum creatinine 
1.13 mg/dl (glomerular filtration rate according to MDRD equa-
tion of 63 ml/min) and mild microscopic hematuria (2–4 eryth-
rocytes/microscopic field, 54% of them dysmorphic; no acan-
thocytes, no casts). Normal serum complement (C 3 /C 4 ) was not-
ed. Her medications currently include nifedipine, ranitidine, 
and doxazosin.
 Review of the Literature 
 A systematic review of the medical literature was done 
by PubMed search up to August 31, 2012; the key words 
‘cryoglobulinemia’, ‘glomerulonephritis’, ‘HCV infec-
tion’, ‘interferon’, ‘rituximab’ were used to identify clini-
cal studies on antiviral (or rituximab, RTX) treatment of 
HCV-associated kidney disease. Review papers and case 
reports were excluded. Some manuscripts were excluded 
as they gave information on patients already reported in 
prior publications  [10, 11] , others gave incomplete results 
 [12–18] .
 We identified 9 clinical studies on antiviral therapy for 
HCV-associated GN (n = 156 unique patients;  fig. 1 )  [19–
27] ; the rate of SVR ranged between 14 and 100%. As list-
ed in  figure 1 , the summary estimate of frequency of SVR 
was 0.49 (95% confidence interval, CI: 0.21, 0.77; random-
effects model). Significant heterogeneity was noted.
 A total of six studies on RTX for HCV-associated glo-
merular disease was considered in this review  [28–33] ; 
only these satisfied our inclusion criteria, i.e. detailed in-
formation on HCV-associated kidney disease at baseline 
and over follow-up. Various reports on RTX therapy for 
symptomatic HCV-associated mixed cryoglobulinemia 
 Fig. 1.  HCV-related GN: viral response after IFN. 
Review: HCVGN/FN
Comparison: 01 Outcomes after IFN for HCV-related GN
Outcome: 01 SVR rate after IFN for HCV-related GN
Study
or subcategory
SVR rate (SE) SVR rate (random)
95% CI
Weight
%
SVR rate (random)
(95% CI)
Year
Mazzaro 0.1420 (0.1319) 11.00 0.14 (–0.12, 0.40) 2000
Alric 0.6666 (0.1111) 11.31 0.67 (0.45, 0.88) 2003
Bruchfeld 0.7140 (0.1700) 10.36 0.71 (0.38, 1.05) 2003
Rossi 0.9999 (0.0574) 11.91 1.00 (0.89, 1.11) 2003
Saadoun 0.5900 (0.1048) 11.40 0.59 (0.38, 0.80) 2006
Garini 0.7500 (0.2160) 9.50 0.75 (0.33, 1.17) 2007
Roccatello 0.1090 (0.0420) 12.02 0.11 (0.03, 0.19) 2007
Abbas 0.1333 (0.0620) 11.87 0.13 (0.01, 0.25) 2008
Saadoun 2 0.4000 (0.1549) 10.62 0.40 (0.10, 0.70) 2010
Total (95% CI) 100.00 0.49 (0.21, 0.77)
Test for heterogeneity: 2 = 194.58, d.f. = 8 (p < 0.00001), I2 = 95.9%
Test for overall effect: Z = 3.46 (p = 0.0005)
–1,000 –500 0 500
Favors treatment Favors control
1,000
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(HCV-MC) with kidney involvement have been pub-
lished; some of them mentioning the ‘partial’ or ‘com-
plete’ remission of kidney disease after RTX, but no clear 
information on daily proteinuria or serum creatinine was 
given  [34–35] . The number of patients with kidney dis-
ease was small (66 unique patients;  table 2 ); renal involve-
ment ranged from proteinuria, nephrotic or nephritic 
syndrome, to chronic kidney disease. All patients had 
symptomatic HCV-MC, the majority being non-cirrhotic 
with HCV genotype 1. As shown in  table 3 , RTX appears 
effective for HCV-related kidney disease; the pooled 
mean difference of decrease in serum creatinine after 
RTX was 0.20 mg/dl (95% CI: –0.09, 0.49; p = 0.55), no 
heterogeneity was noted (p = 0.08; I 2 = 55.1%;  fig. 2 ). In-
formation on daily proteinuria was given in three reports 
only; the pooled mean difference of proteinuria decrease 
after RTX was 1.40 g/24 h (95% CI: 0.75, 2.05; p  ! 0.0001); 
p test for heterogeneity was not significant.
 Discussion 
 HCV has been associated with glomerular lesions in 
native and transplanted kidneys. The exact prevalence of 
these renal manifestations is probably low, and the avail-
able evidence on this issue is limited; to date, the most 
important survey has been done on male veterans hospi-
talized in the USA in the 1990s  [36] ; membranoprolifera-
tive GN was more frequent among HCV positive- than 
HCV-negative individuals (0.36 vs. 0.05%, p  ! 0.0001). 
No difference occurred on membranous nephropathy 
(0.33 vs. 0.19%, p = 0.86).
 Our case emphasizes the efficacy of antiviral therapy 
for HCV-associated GN; the mild kidney disease and the 
absence of aggressive involvement of other organs sug-
gested an antiviral approach. We observed a close rela-
tionship between persistent clearance of HCV viremia 
and remission of urinary abnormalities. Tolerance to an-
tiviral therapy was not excellent as the patient needed 
blood transfusions; however, this side effect disappeared 
after dose reduction of antiviral drugs. She received a 
6-month course of antiviral therapy even if the KDIGO 
guidelines recommend antiviral therapy for at least 12 
months irrespective of HCV genotype  [9] .
 Our systematic review demonstrated the limited num-
ber of studies addressing the antiviral therapy of HCV-
related GN, only small observational studies exist  [37] . In 
addition, the impact of antiviral therapy on long-term 
outcomes of kidney disease remains unclear. As reported 
in  figure 1 , initial studies (based on IFN alone) not sur-
prisingly gave high relapse rates, but with the gold stan-
dard of HCV treatment (pegylated IFN plus ribavirin), 
the viral response was better. Of note, in all patients with 
proteinuria reduction, HCV RNA clearance was docu-
mented at the end of IFN therapy.
 With multiorgan involvement, the antiviral therapy 
may be limited due to treatment failure, adverse effects, 
contraindications, or severe renal disease. On the other 
Review: RTX for HCV-GN
Comparison: 01 Kidney function after RTX
Outcome: 01 Serum creatinine after RTX
Study
or subcategory
n Before RTX
mean (SD)
n After RTX
mean (SD)
WMD (random)
95% CI
Weight
%
VMD (random)
(95% CI)
Year
Quartuccio 5 1.48 (0.49) 5 1.06 (0.25) 20.15 0.42 (–0.06, 0.90) 2006
Petrarca 2 1.66 (0.09) 2 1.69 (0.01) 43.33 –0.03 (–0.16, 0.10) 2007
Saadoun 7 1.18 (0.80) 7 0.90 (0.29) 14.32 0.28 (–0.35, 0.91) 2008
Ferri 38 1.90 (1.10) 38 1.40 (0.85) 22.19 0.40 (–0.04, 0.84) 2011
Total (95% CI) 52 52 100.00 0.20 (–0.09, 0.49)
Test for heterogeneity: 2 = 6.68, d.f. = 3 (p = 0.08), I2 = 55.1%
Test for overall effect: Z = 1.38 (p = 0.17)
–10 –5 0 5
Favors treatment Favors control
10
 Fig. 2. HCV-related GN: serum creatinine after RTX. 
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hand, conventional immunosuppressive therapy may be 
poorly tolerated or ineffective. Therefore, new treatment 
options such as RTX, a human-mouse chimeric monoclo-
nal antibody, have been proposed. RTX binds to the B cell 
surface antigen CD20 and depletes the expanded B cell 
clone or clones producing rheumatoid factor and cryo-
globulins. Several groups have first reported on the effi-
cacy of RTX in patients with symptomatic HCV-MC vas-
culitis resistant or intolerant to IFN-  monotherapy. A 
complete clinical response was reported in 60–70% of 
cases, with cryoglobulin clearance in one third of patients 
 [34, 35] . Recently, two RCTs showed that RTX was supe-
rior to conventional immunosuppressive agents (i.e. cor-
ticosteroids, plasma exchange, and azathioprine or cyclo-
phosphamide) for treating symptomatic HCV-MC  [33, 
38] . No change in HCV viral load was noted following 
RTX therapy, according to one RCT  [38] ; in another RCT, 
the frequency of adverse side effects was higher in the 
RTX than the control group, even if the difference did not 
reach statistical significance (21.5 vs. 10%)  [33] . Thus, a 
word of caution is important as the use of RTX has been 
associated with the activation of various infections, par-
ticularly after solid organ transplantation  [39, 40] .
 The absence of efficacy on HCV clearance is a matter 
of concern, and the high relapse rates observed in some 
reports support the need for antiviral therapy to block the 
infection trigger and obviate long-term liver complica-
tions. A recent prospective controlled trial showed the
superiority of a combination of RTX plus Peg-IFN-  2b-
ribavirin compared to Peg-IFN-  2b-ribavirin alone in 
symptomatic HCV-MC. A complete clinical response was 
noted in 80.9% (17/21) of patients with kidney involve-
ment in the RTX plus Peg-IFN-  2b-ribavirin group, the 
CR being 40% (4/10) among patients with kidney disease 
on Peg-IFN-  2b-ribavirin alone (p  ! 0.04)  [27] . Thus, the 
association of RTX with combined antiviral therapy may 
be an appropriate choice for symptomatic HCV-MC, but 
its safety and efficacy needs to be better addressed.
Table 2.  Rituximab therapy of HCV-associated cryoglobulinemic GN: baseline characteristics and RTX schedule
F irst author
Qu artuccio Petrarca Roccatello Saadoun Ferri De Vita 
Year 2006 2007 2008 2008 2011 2012
Country Italy Italy Italy France Italy Italy
Patients 5 2 12 16 87 28
Age, years 57.2 (45–65) 61.5 61.9 (37–76) 58810.5 61.3811.4 62.8811.4
Male 1 (20%) 1 (50%) NA 3 (19%) 19 (22%) 4 (14%)
HCV genotype 1 3 (60%) NA 6 (54%) 10 (62%) NA NA
Prior antiviral therapy 2 (40%) 1 (50%) 0 7 (100%) NA 14 (50%)
Rheumatoid factor, IU/ml 1.783 (146–3,910) 14,207 512 (272–750) 173.3855.7 NA 501.48891
C4, mg/dl 6.2 (2–12) 6.5 (1–12) 5.2 (4–8) 6.289 NA 6.2788.7
IgM, mg/dl 387.2 NA 480 (250–650) 1808700 NA NA
Kidney disease 5 (100%) 2 (100%) 7 (58%) 7 (43.8%) 38 (43.6%) 7 (25%)
Purpura 80% 100% NA 81% 59% NA
Skin ulcers 0 0 3 (25%) 2 (12.5%) 24 (27%) 5 (17.8%)
Hepatitis or cirrhosis 5 (100%) 2 (100%) NA 4 (25%) 52 (60%) NA
Peripheral neuropathy 2 (40%) 2 (100%) 12 (100%) 13 (81%) 69 (79%) 16 (57%)
RTX schedule 375 mg/m2 per week
(4 doses)
375 mg/m2 per week
(4 doses)
375 mg/m2 per week
(4 + 2 doses)
375 mg/m2 per week
(4 doses) + pegIFN2b 
and ribavirin
375 mg/m2 per week
(4 doses) or 1 g ! 2
(0, 14 day)
1 g ! 2
(0, 14 day)
NA = Not available.
Table 3.  RTX therapy of HCV-associated cryoglobulinemic GN: 
follow-up results on proteinuria (g/24 h) and serum creatinine 
(mg/dl)
First author Daily proteinuria
baseline/follow-up
Serum creatinine
baseline/follow-up
Ferri 2.282.1/0.981.75 1.881.1/1.480.85
Roccatello 1.6/0.3 NA
Quartuccio 1.7481.3/0.280.2 1.4880.49/1.0680.25
De Vita 2 (0.6–7.9)/0.9 (0.5–4.5) 1.6 (0.7–2.8)/1.6 (0.8–0)
Petrarca NA 1.6680.09/1.6980.01
Saadoun 1.682.5/0.180.2 1.1880.8/0.980.29
NA = Not available.
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 Two direct-acting antiviral agents, boceprevir and 
telaprevir, have been recently licensed; they lower the 
activity of the HCV non-structural protein 3-4A serine 
protease and increase the viral response in genotype 1 
HCV infection when used in combination with Peg-IFN 
and ribavirin  [41–42] . Novel guidelines now recom-
mend the triple antiviral therapy for treatment of geno-
type 1 HCV infection  [43] . No studies evaluating effi-
cacy and safety of triple therapy for patients with symp-
tomatic HCV-MC exist, and evidence on direct-acting 
anti-HCV agents is currently limited to patients with in-
tact kidney function.
 Another alternative treatment for HCV-associated 
MC vasculitis is low-dose interleukin-2 (IL-2), a cytokine 
that promotes survival and function of regulatory T cells 
(Tregs). Patients with vasculitis induced by HCV have re-
duced levels of Tregs. Resolution of HCV infection cor-
relates with cure of vasculitis and the recovery of Treg 
levels. Preliminary data suggest that IL-2 supports an at-
tenuation of inflammatory signs in patients with HCV-
induced vasculitis that was refractory to antiviral ther-
apy, RTX or both  [44] . No serious adverse events were 
noted. Additional studies are essential before wider im-
plementation of this treatment strategy.
 In conclusion, our case report emphasizes the efficacy 
and safety of combined anti-HCV therapy for HCV-pos-
itive GN. Viral response was associated with remission of 
urinary abnormalities and improvement of kidney func-
tion. A major concern is the lack of long-term studies on 
patient/kidney outcomes after treatment of HCV-associ-
ated nephropathy. Prospective studies are needed to de-
tail the role of RTX in cryoglobulinemic HCV-positive 
GN; also, the most effective therapy for relapses of cryo-
globulinemia or HCV replication after a successful initial 
course of treatment remains unclear.
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